Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Proteasomal regulation of βc signaling reveals a novel mechanism for cytokine receptor heterotypic desensitization
Margarita Martinez-Moczygemba, David P. Huston
Margarita Martinez-Moczygemba, David P. Huston
Published December 15, 2001
Citation Information: J Clin Invest. 2001;108(12):1797-1806. https://doi.org/10.1172/JCI13877.
View: Text | PDF
Article

Proteasomal regulation of βc signaling reveals a novel mechanism for cytokine receptor heterotypic desensitization

  • Text
  • PDF
Abstract

IL-5, IL-3, and GM-CSF are hematopoietic cytokines that are key mediators of the allergic inflammatory response. The receptors for these three cytokines consist of a cytokine-specific α (Rα) chain and a shared common β (βc) chain. Herein, we demonstrate that agonistic ligation of these receptor subunits rapidly induces proteasomal degradation of the βc, but not the Rα, cytoplasmic domain, resulting in termination of signal transduction and yielding a truncated βc isoform ligated to the Rα subunit. Proteasomal degradation of the βc cytoplasmic domain was also a prerequisite for endocytosis and lysosomal degradation of the ligated receptor subunits. Moreover, proteasome-dependent termination of signaling induced by one βc-engaging cytokine resulted in cellular desensitization to signal transduction by subsequent stimulation with another βc-engaging cytokine. These data provide the first evidence for ligand-dependent proteasomal degradation of the βc cytoplasmic domain, and they establish a novel mechanism for heterotypic desensitization of shared cytokine receptor signaling.

Authors

Margarita Martinez-Moczygemba, David P. Huston

×

Figure 5

Options: View larger image (or click on image) Download as PowerPoint
The ligated IL-5R complex is endocytosed and degraded in lysosomes. (a) ...
The ligated IL-5R complex is endocytosed and degraded in lysosomes. (a) TF1 cells that had been cytokine-starved for 24 hours were left untreated (lanes 1, 3, and 5) or were pretreated with 10 μM cytochalasin D (lanes 2, 4, and 6) for 1 hour prior to IL-5 stimulation (10 ng/ml) for the indicated times. Whole-cell lysates were prepared, and proteins were immunoprecipitated with anti-βc monoclonal antibody and immunoblotted with anti-βc polyclonal antibodies (top panel). The membrane was stripped and reprobed with anti–IL-5Rα antibodies (bottom panel). Note the accumulation of βc, βIP, and IL-5Rα in the presence of the inhibitor in lane 6. (b) Same as in a, top panel, except that cells were pretreated with 200 nM bafilomycin A1 in lanes 2, 4, and 6. Note the accumulation of βIP in the presence of bafilomycin A1 in lane 6 (bottom arrow).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts